References
- Pergolizzi JV, Taylor R, Nalamachu S, et al. Challenges of treating patients with chronic pain with dysphagia (CPD): physician and patient perspectives. Curr Med Res Opin 2014;30:191-202
- Argoff CE, Kopecky EA. Patients with chronic pain and dysphagia (CPD): unmet medical needs and pharmacologic treatment options. Curr Med Res Opin 2014;30:2543-59
- Institute of Medicine. Relieving pain in America: a blueprint for transforming prevention, care, education, and research. Washington, DC, USA: The National Academies Press, 2011
- Nicholson B. Benefits of extended-release opioid analgesic formulations in the treatment of chronic pain. Pain Pract 2009;9:71-81
- Webster L. Update on abuse-resistant and abuse-deterrent approaches to opioid formulations. Pain Med 2009;10(Suppl 2):S124-S33
- Kadian (morphine sulfate extended-relase capsules, for oral use, CII). Morristown, NJ, USA: Actavis Inc, 2014
- Avinza (morphine sulfate extended-release capsules). New York, NY, USA: Pfizer Inc, 2014
- OxyContin (oxycodone hydrochloride) extended-release tablets, for oral use, CII. Stamford, CT, USA: Purdue Pharma LP, 2015
- Opana ER (oxymorphone hydrochloride) extended-release tablets, for oral use, CII. Malvern, PA, USA: Endo Pharmaceuticals Inc, 2014
- Hysingla (hydrodone bitartrate) extended-release tablets, for oral use, CII. Stamford, CT, USA: Purdue Pharma LP, 2015
- Embeda (morphine sulfate and naltrexone hydrochloride capsule, extended-release). New York, NY, USA: Pfizer Inc, 2014
- Fine PG, Portenoy RK, and the Ad Hoc Expert Panel on Evidence Review and Guidelines for Opioid Rotation. Establishing “best practices” for opioid rotation: conclusions of an expert panel. J Pain Symptom Manage 2009;38:418-25
- Fleming AB, Carlson DR, Varanasi RK, et al. Evaluation of an extended-release, abuse-deterrent, microsphere-in-capsule analgesic for the management of patients with chronic pain with dysphagia (CPD). Pain Pract 2016;16:334-44
- Gudin J, Levy-Cooperman N, Kopecky EA, et al. Comparing the effect of tampering on the oral pharmacokinetic profiles of two extended-release oxycodone formulations with abuse-deterrent properties. Pain Med 2015;16:2142-51
- Kopecky EA, Fleming AB, Noonan PK, et al. Impact of physical manipulation on in vitro and in vivo release profiles of oxycodone DeterX: an extended-release, abuse-deterrent formulation. J Opioid Manag 2014;10:233-46
- Katz N, Kopecky EA, O’Connor M, et al. A phase 3, multicenter, randomized, double-blind, placebo-controlled, safety, tolerability, and efficacy study of Xtampza ER in patients with moderate-to-severe chronic low back pain. Pain 2015;156:2458-67
- Center for Drug Evaluation and Research. Guidance for industry: dissolution testing of immediate release solid oral dosage forms. Silver Spring, MD, USA: US Department of Health and Human Services, Food and Drug Administration, 1997
- Center for Drug Evaluation and Research. Guidance for industry: food-effect bioavailability and fed bioequivalence studies. Silver Spring, MD, USA: US Department of Health and Human Services, Food and Drug Administration, 2002
- Xtampza (oxycodone) extended-release capsules, for oral use, CII. Canton, MA, USA: Collegium Pharmaceutical Inc, 2016
- Tisdale JE, Miller DA (eds). Drug-induced diseases: prevention, detection, and management, 2nd edn. Bethesda, MD, USA: American Society of Health-System Pharmacists, 2010